white → brown1 → brown2
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
25H-NBOMe
2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
2C-H-NBOMe, NBOMe-2C-HOpen in Piru
25H-NBOMe is an N-benzylated phenethylamine in the NBOMe class.1 It is a derivative of 2C-H2 and it has been reported to have higher in vitro potency at the 5-HT2A receptor than 2C-H.2 Ralf Heim first described it in the scientific literature at the Free University of Berlin by 2003. Its suspected stimulant and blood vessel-constricting properties may be dangerous at high doses, and a heavy body load is expected.
Dosage & Duration
Duration
Onset30-90 minutes
After Effects2-3 hours
Total3-5 hours
Subjective Effects
Subjective Effects not written up yet
Pharmacology
Pharmacodynamics
25H-NBOMe acts as a potent full agonist at the human serotonin 5-HT2A receptor. It binds to this receptor with a Ki of 2.83 nM3 and activates it with an EC50 of 15.3 nM.3
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE
Tolerance
Tolerance not written up yet
Harm Potential
Addiction & Dependence
Psychological
LowHas shown reinforcing effects in rodent studies, including conditioned place preference and self-administration, suggesting some potential for psychological reinforcement.
Toxicity
Suspected vasoconstrictive properties may pose risks at high doses; the extent of cardiovascular danger in humans remains poorly characterized.
History & Culture
By 2003, Ralf Heim at the Free University of Berlin had provided the first description of 25H-NBOMe in the scientific literature.
Legality
By Country
Illegal2
SwedenIllegalLäkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika, Förteckning I, as amended through HSLF-FS 2026:2645678
25H-NBOMe, identified as 2-(2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin, is expressly listed in Förteckning I of Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. The Government added it under Hallucinogener in Annex 1 to Förordning (1992:1554), and Läkemedelsverket placed it in Förteckning I; both measures took effect on 1 August 2013. Förteckning I covers substances, plant materials, and fungi that normally have no medical use. Under Narkotikastrafflag (1968:64), unauthorized transfer, production for abuse, acquisition for transfer, procurement, processing, packaging, transport, storage, possession, use, sale, and offering for sale are prohibited; unlawful import and export are separately governed by the smuggling statute.
United KingdomIllegal25H-NBOMe is covered as a Class A drug by the generic structural provisions in Part I of Schedule 2 to the Misuse of Drugs Act 1971. It is 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. Its 2,5-dimethoxyphenethylamine portion falls within paragraph 1(c), which covers phenethylamines bearing alkoxy ring substituents, and its N-(2-methoxybenzyl) substitution falls within paragraph 1(f), which covers a benzyl substituent on a paragraph 1(c) compound whether or not the benzyl phenyl ring is substituted. Paragraph 1(f) took effect on 10 June 2014, placing groups of NBOMe compounds under permanent Class A control. Possession, possession with intent to supply, production, supply, import, and export are prohibited except as permitted by applicable regulations, licences, or statutory defences.
References
Source Pages
Citations
Further Reading
Braden MR et al. (2006) N-benzyl phenethylamines as potent 5-HT2A receptor agonists
Johnson RD et al. (2014) LC-MS-MS evaluation of NBOMe compounds
Poklis JL et al. (2014) NBOMe intoxication case report with 25B-NBOMe quantification- Pottie E et al. (2021) Serotonin 2A receptor activation by 25H-NBOMe positional isomers
- Suzuki J et al. (2015) Toxicities associated with NBOMe ingestion: systematic review
Zawilska JB & Kacela M (2020) NBOMes - Highly potent and toxic alternatives of LSD- Eshleman et al. 2018 - Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed: this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25H-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
